MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) [Yahoo! Finance]
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: Yahoo! Finance
MindMed has announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD. This marks a pivotal moment in the company's journey towards advancing a novel treatment option for the 20 million people in the U.S. living with GAD. Was this helpful? Yes No What is the expected timeline for the completion of the Phase 3 Voyage study and the initiation of the Panorama study? The Company expects topline readout for the Voyage study (Part A results) in the first half of 2026. The Panorama Study, the second Phase 3 trial, will be conducted in the U.S. and Europe and is on track to initiate in the first half of 2025. Was this helpful? Yes No What is the design of the Phase 3 Voyage study, and what are its primary endpoints? The 52-week Voyage study will be conducted in two parts: Part A, a 12-week, randomized, double-blind, placebo-controlled, parallel group pe
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- Novo Holdings completes purchase of Catalent [Seeking Alpha]Seeking Alpha
- Novo Holdings Completes Acquisition of Catalent [Yahoo! Finance]Yahoo! Finance
- Novo Holdings Completes Acquisition of CatalentBusiness Wire
- MindMed doses first subject in trial of tablets for generalised anxiety disorder [Yahoo! Finance]Yahoo! Finance
- Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say [Yahoo! Finance]Yahoo! Finance
CTLT
Earnings
- 8/29/24 - Miss
CTLT
Sec Filings
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- CTLT's page on the SEC website